awmsg logo



thalidomide (Thalidomide Celgene®)


Reference No. 309

Publication date:
17/03/2009


Appraisal information

thalidomide (Thalidomide Celgene®) 50 mg capsule


Company: Celgene Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 27/01/2009
AWMSG meeting date: 25/02/2009
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 0109
Ministerial ratification: 16/03/2009

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA228) NICE GUIDANCE ISSUED JULY 2011 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Thalidomide (Thalidomide Pharmion®) is recommended for use within NHS Wales in combination with melphalan and prednisone* as first line treatment of patients with untreated multiple myeloma, aged ≥ 65 years or ineligible for high dose chemotherapy. It should only be prescribed and dispensed according to the Thalidomide Pharmion Pregnancy Prevention Programme. AWMSG is of the opinion that thalidomide (Thalidomide Pharmion®) is not suitable for shared care within NHS Wales. *The licence and trials specify the use of prednisone. This is not available in the UK, where a direct substitution of prednisolone for prednisone is made as they are considered dose-equivalent.
Final Appraisal Recommendation (FAR)
Download